Jemperli

(dostarlimab)

Jemperli 500 MG in 10 mL Injection

NO BLACK BOX WARNING

Dosage & administration

* JEMPERLI, in combination with carboplatin and paclitaxel, for dMMR or MSI-H primary advanced or recurrent endometrial cancer: 500 mg every 3 weeks for 6 doses followed by 1,000 mg monotherapy every 6 weeks.
* JEMPERLI, as a single agent, for dMMR recurrent or advanced endometrial cancer: 500 mg every 3 weeks for 4 doses followed by 1,000 mg every 6 weeks.
* JEMPERLI, as a single agent, for dMMR recurrent or advanced solid tumors: 500 mg every 3 weeks for 4 doses followed by 1,000 mg every 6 weeks.
* Administer as an intravenous infusion over 30 minutes.
* For complete dosing instructions, see full prescribing information.

Most viewed Jemperli resources

OTHEREnroll in Patient Savings Program

biomarker testing

Jemperli clinical details

Genetic testing requirements were obtained from the NCCN guidelines for each cancer type.

drug label

Jemperli prescribing information

Contact Medical Science Liaison Report Adverse Event

prior authorization

Jemperli prior authorization resources

Most recent Jemperli prior authorization forms

View By Payer

Updated: May 31, 2023Cigna - Jemperli Prior Authorization Form

Updated: May 24, 2023Aetna - Jemperli Prior Authorization Form

Updated: May 23, 2023Aetna - Medicare Part B Jemperli Prior Authorization Form

PDFComplete Letter of Medical Necessity

PDFCoverage Authorization Appeals

Learn More

Benefits investigation

PDFJemperli Service Request Form

Learn More

financial assistance

Jemperli financial assistance options

Co-pay savings program

commercial only

PDFJemperli Service Request Form

OTHEREnroll in Patient Savings Program

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Foundation programs

under insured

no insurance

goverment insurance

65+

PDFJemperli Service Request Form

OTHERGSK Patient Assistance Program Eligibility & Enrollment

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.

How to sign up

Patients submit proof of out-of-pocket drug costs to charities for reimbursement

patient education

Jemperli patient education

Getting started on Jemperli

To share resource; ask patient to:

1.Pull out phone

2.Open camera

3.Scan QR code with camera

4.Tap link